Kenneth B. Kirby
President & Chief Executive Officer

Mr. Kirby founded TTI in 1990 and has overseen both operations and technical
development for TTI. He is the co-inventor of the TDS® technology. In the late
1980s, he identified a novel transdermally active pharmaceutical compound,
negotiated a license for its patents, raised the seed capital and subsequent
mezzanine financing, formulated the product, designed the packaging, engaged
its manufacturing and began marketing the product in the United States. Mr. Kirby
received a B.A. in pre-medical studies from Florida State University with an
emphasis in clinical psychopharmacology. He is a member of Phi Beta Kappa
and the American Chemical Society. Kirby also is a Paul Harris Fellow of the
Rotary International Foundation and serves on the Board of Advisors of the
Jim Moran Institute for Global Entrepreneurship at Florida State University.

Ronald J. Gourley
Executive Vice President, Global Development

Ron’s diverse experience formed a unique path that led him to TransDermal Delivery Solutions Corporation. After earning a Bachelor of Arts degree in Marketing from the University of Wisconsin in Whitewater, Ron launched his professional career in sales and marketing for food industry giants Hormel Foods, Oscar Mayer, and PepsiCo. By 1991, Ron had risen through the ranks at Pepsi to become a National Director of Sales and Marketing for Non-Commercial Accounts. In 1993, he left corporate business to become an entrepreneur. Ron co-founded The Activ Group, a company with patented technologies designed to leverage molecular science for intra-dermal delivery of complex nutritional compounds for wound care, active anti-microbial hand antiseptics, and cosmetic skin care. As the company’s president and chief executive officer, he raised working capital, built a leadership team, managed in-house and third party manufacturing, developed corporate and product brands, and launched multiple products in national and international markets.  Ron's entrepreneurial career also involved participation in the development of companies focused on using bio-organic chemistry for environmental remediation.

Chandan A.S. Alam, B. Sc., M.D.
Vice President, Development

Chandan A.S. Alam is currently the Vice President and Chief Scientific Officer. Dr. Alam is also a Director. His main area of interest is the transdermal delivery of drugs and he has completed five successful clinical trials of the TDS®.  From 2005 to 2007 Dr. Alam was Senior Scientist and head of the Experimental Pathology group at the William Harvey Research Institute. Dr. Alam is a Director with responsibility for Academic Collaborations – William Harvey Research Institute, a Director with responsibility for Business Development – William Harvey Research Limited, which is the commercial entity for technology transfer at the institute. Dr. Alam has published 52 papers on angiogenesis, various animal models of disease and transdermal delivery of drugs and has presented widely at international conferences.  Dr. Alam is co-inventor of two US Patents - No. 5,847,002 and 6,596,703 which have developed from his work.  Dr. Alam is a member of the East London and City Medical Ethics Committee. Dr. Alam began his research collaboration with TTI on July 1, 2001.  Dr. Alam received his Bachelor of Science (BSc) from London Guildhall University and his MD from St. Georges School of Medicine, Grenada.  Dr. Alam also has a Bachelors degree in Architecture from the University of London.